HomeCompareCFFS vs MRK

CFFS vs MRK: Dividend Comparison 2026

CFFS yields 17.73% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CFFS wins by $5.8K in total portfolio value
10 years
CFFS
CFFS
● Live price
17.73%
Share price
$11.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.5K
Annual income
$5,247.63
Full CFFS calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — CFFS vs MRK

📍 CFFS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCFFSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CFFS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CFFS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFFS
Annual income on $10K today (after 15% tax)
$1,507.09/yr
After 10yr DRIP, annual income (after tax)
$4,460.49/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $4,136.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFFS + MRK for your $10,000?

CFFS: 50%MRK: 50%
100% MRK50/50100% CFFS
Portfolio after 10yr
$60.6K
Annual income
$7,680.70/yr
Blended yield
12.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CFFS
No analyst data
Altman Z
5.1
Piotroski
2/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFFS buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCFFSMRK
Forward yield17.73%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$63.5K$57.7K
Annual income after 10y$5,247.63$10,113.78
Total dividends collected$33.8K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CFFS vs MRK ($10,000, DRIP)

YearCFFS PortfolioCFFS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,473$1,773.05$11,213$373.04+$1.3KCFFS
2$15,413$2,066.85$12,667$512.06+$2.7KCFFS
3$18,879$2,386.94$14,439$708.14+$4.4KCFFS
4$22,933$2,732.41$16,640$988.16+$6.3KCFFS
5$27,640$3,102.01$19,432$1,394.07+$8.2KCFFS
6$33,069$3,494.15$23,057$1,992.90+$10.0KCFFS
7$39,291$3,906.97$27,889$2,894.79+$11.4KCFFS
8$46,380$4,338.36$34,518$4,286.29+$11.9KCFFS
9$54,412$4,786.05$43,912$6,494.35+$10.5KCFFS
10$63,469$5,247.63$57,714$10,113.78+$5.8KCFFS

CFFS vs MRK: Complete Analysis 2026

CFFSStock

CF Acquisition Corp. VII does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on potential target companies in the financial services, healthcare, real estate services, technology, and software industries. CF Acquisition Corp. VII was incorporated in 2020 and is based in New York, New York.

Full CFFS Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CFFS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFFS vs SCHDCFFS vs JEPICFFS vs OCFFS vs KOCFFS vs MAINCFFS vs JNJCFFS vs ABBVCFFS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.